Elevation Oncology Inc expected to post a loss of 22 cents a share - Earnings Preview

Elevation Oncology

30/07/2024 20:29

* Elevation Oncology Inc  ELEV.OQ   ELEV.O  is expected
to show no
change in quarterly revenue when it reports  results on August 1
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Elevation Oncology Inc
is for
a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Elevation
Oncology Inc is $8.00​, above​ its last closing price of $2.87.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.20       -0.20      -0.23     Missed  -13.7
 Dec. 31 2024  -0.27       -0.24      -0.19     Beat    20
 Sep. 30 2023  -0.31       -0.32      -0.25     Beat    21.9​
 Jan. 1 0001   -0.26       -0.32      -0.37     Missed  -15
 ​​Mar.        -0.62       -0.59      -0.72     Missed  -21.7
 31 2023                                                
 Dec. 31 2022  -1.33       -0.78      -0.82     Missed  -4.9​
 Sep. 30 2022  -1.33       -1.30      -1.67     Missed  -28.7
 Jun. 30 2022  -0.79       -0.79      -0.86     Missed  -9.2
 This summary was machine generated July 30 at 19:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)